Optical coherence tomography as a potential readout in clinical trials

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Optical coherence tomography (OCT) is a noninvasive tool used for measuring tissue at micrometer resolution. It has been extensively applied to ocular pathologies and is now being studied as a biomarker in various neurologic conditions. The retina represents a unique environment for study, with unmyelinated axons that directly synapse into the central nervous system. When trying to quantify axonal degradation in neurologic disease, the currently used imaging modalities are limited in sensitivity and specificity. Early data suggest that several neurologic conditions have pathologic changes in the retinal nerve fiber layer of the eye, creating a potential surrogate marker for neurodegeneration. OCT has the potential to become a noninvasive, reproducible test for axonal degeneration that could become an invaluable tool for measuring the efficacy of potential neuroprotective agents. If the natural history of neurodegeneration, as measured by OCT, can be documented in diseases such as Alzheimergs, Parkinsongs and multiple sclerosis, then OCT can be used to measure alterations in the rate of degeneration when treatment is applied. Thus, OCT represents a new, promising technology for documenting outcomes in neuroprotection trials.

Original languageEnglish (US)
Pages (from-to)153-160
Number of pages8
JournalTherapeutic Advances in Neurological Disorders
Volume3
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Optical Coherence Tomography
Clinical Trials
Nervous System
Biomarkers
Neuroprotective Agents
Nervous System Diseases
Natural History
Nerve Fibers
Synapses
Multiple Sclerosis
Axons
Retina
Central Nervous System
Pathology
Technology
Sensitivity and Specificity

Keywords

  • Macula
  • Multiple sclerosis
  • Neurodegeneration
  • Optical coherence tomography
  • Retinal nerve fiber layer

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Pharmacology

Cite this

@article{437a363926b64880a3c75f2117b35e65,
title = "Optical coherence tomography as a potential readout in clinical trials",
abstract = "Optical coherence tomography (OCT) is a noninvasive tool used for measuring tissue at micrometer resolution. It has been extensively applied to ocular pathologies and is now being studied as a biomarker in various neurologic conditions. The retina represents a unique environment for study, with unmyelinated axons that directly synapse into the central nervous system. When trying to quantify axonal degradation in neurologic disease, the currently used imaging modalities are limited in sensitivity and specificity. Early data suggest that several neurologic conditions have pathologic changes in the retinal nerve fiber layer of the eye, creating a potential surrogate marker for neurodegeneration. OCT has the potential to become a noninvasive, reproducible test for axonal degeneration that could become an invaluable tool for measuring the efficacy of potential neuroprotective agents. If the natural history of neurodegeneration, as measured by OCT, can be documented in diseases such as Alzheimergs, Parkinsongs and multiple sclerosis, then OCT can be used to measure alterations in the rate of degeneration when treatment is applied. Thus, OCT represents a new, promising technology for documenting outcomes in neuroprotection trials.",
keywords = "Macula, Multiple sclerosis, Neurodegeneration, Optical coherence tomography, Retinal nerve fiber layer",
author = "Benjamin Greenberg and Elliot Frohman",
year = "2010",
month = "5",
doi = "10.1177/1756285610368890",
language = "English (US)",
volume = "3",
pages = "153--160",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Optical coherence tomography as a potential readout in clinical trials

AU - Greenberg, Benjamin

AU - Frohman, Elliot

PY - 2010/5

Y1 - 2010/5

N2 - Optical coherence tomography (OCT) is a noninvasive tool used for measuring tissue at micrometer resolution. It has been extensively applied to ocular pathologies and is now being studied as a biomarker in various neurologic conditions. The retina represents a unique environment for study, with unmyelinated axons that directly synapse into the central nervous system. When trying to quantify axonal degradation in neurologic disease, the currently used imaging modalities are limited in sensitivity and specificity. Early data suggest that several neurologic conditions have pathologic changes in the retinal nerve fiber layer of the eye, creating a potential surrogate marker for neurodegeneration. OCT has the potential to become a noninvasive, reproducible test for axonal degeneration that could become an invaluable tool for measuring the efficacy of potential neuroprotective agents. If the natural history of neurodegeneration, as measured by OCT, can be documented in diseases such as Alzheimergs, Parkinsongs and multiple sclerosis, then OCT can be used to measure alterations in the rate of degeneration when treatment is applied. Thus, OCT represents a new, promising technology for documenting outcomes in neuroprotection trials.

AB - Optical coherence tomography (OCT) is a noninvasive tool used for measuring tissue at micrometer resolution. It has been extensively applied to ocular pathologies and is now being studied as a biomarker in various neurologic conditions. The retina represents a unique environment for study, with unmyelinated axons that directly synapse into the central nervous system. When trying to quantify axonal degradation in neurologic disease, the currently used imaging modalities are limited in sensitivity and specificity. Early data suggest that several neurologic conditions have pathologic changes in the retinal nerve fiber layer of the eye, creating a potential surrogate marker for neurodegeneration. OCT has the potential to become a noninvasive, reproducible test for axonal degeneration that could become an invaluable tool for measuring the efficacy of potential neuroprotective agents. If the natural history of neurodegeneration, as measured by OCT, can be documented in diseases such as Alzheimergs, Parkinsongs and multiple sclerosis, then OCT can be used to measure alterations in the rate of degeneration when treatment is applied. Thus, OCT represents a new, promising technology for documenting outcomes in neuroprotection trials.

KW - Macula

KW - Multiple sclerosis

KW - Neurodegeneration

KW - Optical coherence tomography

KW - Retinal nerve fiber layer

UR - http://www.scopus.com/inward/record.url?scp=77953385483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953385483&partnerID=8YFLogxK

U2 - 10.1177/1756285610368890

DO - 10.1177/1756285610368890

M3 - Article

VL - 3

SP - 153

EP - 160

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

IS - 3

ER -